||PsychopharmaStahlogy Show: Psychedelic Assisted Psychotherapy
The PsychopharmaStahlogy Show is a special podcast series released on the NEI Podcast. In the first three part series, Dr. Andrew Cutler asks Dr. Stephen Stahl important questions relating to psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders.
Episodes released under this theme include:
Transcript from Part I - Episode 98
DR STAHL: When we understand these drugs, the rate at which they occupy the receptors, the degree to which they occupy the receptors, how fast they come off the receptors, are all changing the drug into different things. So what we want to do is tweak the kind of experience that you're having so that your memory can be modified, but you're not freaking out or having a bad experience or abusing it. As it's possible to do that by dosing, that not only the absolute dose, but the way it's dosed, so that how fast it's on, how long it's on, how fast it’s off the receptor.
DR CUTLER: So you've mentioned a bad experience or bad trip or freaking out, and we’ve mentioned obviously some of the potential cardiovascular effects and things like this. What other risks are there with these types of treatments?
DR STAHL: That they don't work, I suppose is one of the other ones. That you're just wasting time and you raising hope. But I think that you’re playing with fire here. Is it possible that you will change memories you want to keep? Is it possible that you will change the underlying synaptogenesis in a bad direction because we don't really know what the heck we’re doing? So I think this is basically something that needs to be carefully thought through and not just say, well, let's approve psilocybin and any psychotherapy goes. Or like my acquaintance in Santa Barbara is doing, give an IM (intramuscular) shot ketamine and then just do it what make sense to you. That could actually cause more harm than good.
DR CUTLER: Ketamine as we know can cause significant elevations of blood pressure, and you mentioned the same with MDMA. The kinds of things that can do. There's probably a lot of risks that we don't know, and unless these things are studied in really careful, rigorous clinical trials, it's really hard to get an accurate risk benefit assessment.
Subscribe to NEI Podcast so you don't miss an episode!